Patents Examined by Stacey N MacFarlane
  • Patent number: 11187708
    Abstract: The present invention relates to diagnostic methods, reagents, and kits for detecting and diagnosing Early Stage Parkinson's disease.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: November 30, 2021
    Assignee: Rowan University
    Inventor: Robert G. Nagele
  • Patent number: 11180543
    Abstract: The invention provides methods for the treatment of neonatal hypoxia and associated white matter disease or injury, particularly in infant, including neonatal, animals, particularly Periventricular Leukomalacia (PVL) comprising administering one or more CNS reactive antibody, particularly selected from IgM12, IgM22, IgM42 and IgM46. Compositions for use in treatment of white matter disease or injury in infants, particularly PVL are provided. The invention provides methods for alleviation of neuromotor or neurodevelopmental deficits associated with neonatal hypoxia and associated with white matter injury, including PVL, in an infant.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: November 23, 2021
    Assignee: Mayo Foundation For Medical Education and Research
    Inventors: Jens O. Watzlawik, Arthur E. Warrington, Moses Rodriguez, William A. Carey
  • Patent number: 11173140
    Abstract: Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, com-prising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecut-ive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a dis-ease or condition associated with neuronal or synaptic loss according to the disclosed regimens.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: November 16, 2021
    Assignee: COGNITIVE RESEARCH ENTERPRISES, INC.
    Inventor: Daniel L. Alkon
  • Patent number: 11167007
    Abstract: Disclosed herein, inter alia, are FOXM1 modulators and methods for modulating the activity of androgen receptors in neuronal cells to treat various diseases, such as spinal-bulbar muscular atrophy, amyotrophic lateral sclerosis, and Alzheimer's disease.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: November 9, 2021
    Assignee: CITY OF HOPE
    Inventors: Jeremy Jones, Maya Otto-Duessel
  • Patent number: 11142570
    Abstract: Disclosed herein are anti-?-synuclein antibodies which preferentially bind to oligomeric ?-synuclein over monomeric ?-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: October 12, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael K. Ahlijanian, Jere Ernest Meredith, Jr., Nino Devidze, John David Graef, Edward L. Halk
  • Patent number: 11136548
    Abstract: Described herein are cell culture media useful for the differentiation of human pluripotent stem cells into microglia. The methods described herein relate to in vitro generation of expandable, bankable, microglial cells by directed differentiation from human pluripotent stem cells (induced or embryonic). Using only defined cell culture media, differentiation of pluripotent stem cells is directed down a mesodermal path, in a rapid and scalable fashion, to generate cells adopting signatures of their in vivo counterparts, including gene expression, protein marker expression and functionality.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: October 5, 2021
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Julien Muffat, Yun Li, Rudolf Jaenisch
  • Patent number: 11129866
    Abstract: A method of inhibiting aberrant valosin-containing protein (VCP) accumulation in the mitochondria of a nerve cell includes administering to the nerve cell a therapeutic agent that inhibits the binding or complexing of VCP with a polyglutamine protein.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: September 28, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Xin Qi
  • Patent number: 11117963
    Abstract: The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: September 14, 2021
    Assignees: KYOWA HAKKO KIRIN CO., LTD., KAGOSHIMA UNIVERSITY
    Inventors: Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Yuji Ito
  • Patent number: 11116815
    Abstract: Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-?), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and ?-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: September 14, 2021
    Assignee: The Penn State Research Foundation
    Inventors: Gong Chen, Gang-Yi Wu, Lei Zhang, Jiu-Chao Yin, Hana Yeh, Ning-Xin Ma, Grace Lee
  • Patent number: 11112407
    Abstract: The present invention relates to a method for diagnosing a disease, comprising the step detecting in a sample an autoantibody binding to the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, a use of a membrane-associated human Na(+)/K(+) ATPase or a variant thereof for the diagnosis of a disease, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase or a variant thereof, for use in the treatment of a disease, an autoantibody binding to said polypeptide and a method for isolating such autoantibody, a pharmaceutical composition, medical or diagnostic device or test kit comprising the polypeptide.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: September 7, 2021
    Assignee: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Lars Komorowski, Madeleine Scharf, Ramona Miske, Yvonne Denno, Inga-Madeleine Dettmann, Christian Probst, Fedor Heidenreich, Ralf GieƟ
  • Patent number: 11104719
    Abstract: Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism).
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: August 31, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Yong-Jian Geng
  • Patent number: 11090355
    Abstract: The disclosure relates to a pharmaceutical composition comprising any one or combination of PIF peptides or analogs or pharmaceutically acceptable salts thereof. Methods of treating cellular neurodamage or neurotrauma to the peripheral or central nervous system using the one or a combination of PIF peptide or analogs thereof or pharmaceutically acceptable salts thereof is also disclosed.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: August 17, 2021
    Assignee: BIOINCEPT, LLC
    Inventor: Eytan R. Barnea
  • Patent number: 11078298
    Abstract: The invention provides anti-UCH-L1 antibodies and anti-GFAP antibodies and their use in vitro detection of UCH-L1 and GFAP, respectively, in a sample from an individual, such as an individual known or suspected of having a brain injury or damage, for example, neurological damage such as mild traumatic brain injury. Also provided are methods, systems and kits for diagnosing brain injury or damage, such as neurological damage, in an individual with the aforementioned antibodies as well as compositions comprising the anti-UCH-L1 antibodies and anti-GFAP antibodies.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: August 3, 2021
    Assignee: BANYAN BIOMARKERS, INC.
    Inventors: Michael Catania, Ronald L. Hayes
  • Patent number: 11072639
    Abstract: Disclosed herein are multifunctional polypeptides comprising a first domain comprising an anti-tau antigen binding domain and a second domain comprising a proteasome-targeting PEST motif, and methods for using these polypeptides in treatment of tauopathies.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: July 27, 2021
    Assignee: Regenerative Research Foundation
    Inventors: Sally Temple, Anne Messer, David Butler
  • Patent number: 11045533
    Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: June 29, 2021
    Inventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Stephen Gillies
  • Patent number: 11040088
    Abstract: The present invention relates to the intrathecal (IT) administration of recombinant enzyme to treat lysosomal storage disorders. In an exemplary embodiment, intrathecal administration of human ?-L-iduronidase (rhIDU) injections in MPS I affected animals resulted in significant enzyme uptake, significant rh-iduronidase activity in brain and meninges and a decrease of glycosaminoglycan (GAG) storage in cells of MPS I subjects to that of normal subjects. Intrathecal administration proved more effective than intravenous treatment at alleviating MPS I symptoms, indicating it is a useful method of treating lysosomal storage disorders.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: June 22, 2021
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventor: Emil D. Kakkis
  • Patent number: 11034739
    Abstract: Disclosed are conjugates and compositions comprising an amyloid beta binding protein conjugated to a MerTK ligand. Disclosed are methods of clearing amyloid beta aggregates from a subject comprising administering a therapeutically effective amount of the conjugates and compositions comprising an amyloid beta binding protein conjugated to a MerTK ligand. Disclosed are methods of treating Alzheimer's Disease comprising administering to a subject in need thereof a therapeutically effective amount of conjugates and compositions comprising an amyloid beta binding protein conjugated to a MerTK ligand.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: June 15, 2021
    Assignee: The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University of Nevada
    Inventor: Nora Blanca Caberoy
  • Patent number: 11035866
    Abstract: The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject. Also provided are methods for detecting seizure, methods for predicting seizure, use of sICAM-5 in the treatment of seizure, methods for assessing the effectiveness of a treatment of seizure, and diagnostic kits.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: June 15, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John Robert Pollard, Peter B. Crino
  • Patent number: 11007232
    Abstract: The present invention is based in part methods for treating neurodegenerative diseases and disorders. Specifically, the present invention disclose methods for treating neurodegenerative disorders suing neural stem cells (NSCs) and/or pluripotent stem cell (PSC) derived neurons or neuron precursor cells. The present invention also discloses methods to induce endogenous dopaminergic neurons to release dopamine and increase the levels of dopamine in a subject.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: May 18, 2021
    Assignee: International Stem Cell Corporation
    Inventors: Russell A. Kern, Rodolfo Gonzalez, Ibon Garitaonandia
  • Patent number: 11008403
    Abstract: The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: May 18, 2021
    Assignees: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus, Yin Zhang, Joy Yu Zuchero, Jessica Couch, Mark S Dennis, James A Ernst, Gregory A Lazar